Weiss Multi-Strategy Advisers’s Charles River Laboratories CRL Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-35,805	Closed	-$7.23M	–	662
2023 Q1	$7.23M	Sell	35,805 -3,272	-8%	-$742K	0.17%	186
2022 Q4	$8.52M	Sell	39,077 -1,058	-3%	-$231K	0.24%	138
2022 Q3	$7.9M	Buy	+40,135	New	+$8.66M	0.21%	156
2014 Q2	–	Sell	-3,610	Closed	-$218K	–	756
2014 Q1	$218K	Sell	3,610 -630	-15%	-$36.7K	﹤0.01%	895
2013 Q4	$225K	Buy	+4,240	New	+$213K	﹤0.01%	879

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Weiss Multi-Strategy Advisers's CRL Position: Q2 2023 in Review

Weiss Multi-Strategy Advisers sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 35,805 shares — an estimated $7.23M sold.

Weiss Multi-Strategy Advisers first reported a position in CRL in Q4 2013 and held it in 5 quarters. The position peaked at $8.52M in Q4 2022. 611 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

Weiss Multi-Strategy Advisers reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 35,805 Charles River Laboratories shares in Q2 2023, an estimated $7.23M.
Weiss Multi-Strategy Advisers first reported a position in Charles River Laboratories in Q4 2013 and held it in 5 quarters.
Weiss Multi-Strategy Advisers's Charles River Laboratories position peaked at $8.52M in Q4 2022.
611 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.